{
    "nctId": "NCT01566721",
    "briefTitle": "A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer",
    "officialTitle": "A Phase III Prospective, Two-Cohort Non-Randomized, Multi-Centre, Multinational, Open-Label Study to Assess the Safety of Assisted- and Self-Administered Subcutaneous Trastuzumab as Therapy in Patients With Operable HER2-Positive Early Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2577,
    "primaryOutcomeMeasure": "Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed early invasive HER2-positive carcinoma of the breast with no evidence of residual, locally recurrent, or metastatic disease and defined as clinical Stage I to IIIC that is eligible for treatment with Herceptin\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Screening left ventricular ejection fraction (LVEF) greater than or equal to (\u2265) 55%\n\nExclusion Criteria:\n\n* Previous neoadjuvant or adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent\n* History of other malignancy except for curatively treated carcinoma in situ of the cervix, basal cell carcinoma, or curatively treated malignancies (other than breast cancer) where the participant has been disease-free for at least 5 years\n* Past history of ductal carcinoma in situ treated with any systemic therapy or with radiation therapy to the ipsilateral breast where invasive cancer subsequently developed\n* Metastatic disease\n* Inadequate bone marrow, hepatic, or renal function\n* Serious cardiac or cardiovascular disease including uncontrolled hypertension or history of hypertensive crisis or hypertensive encephalopathy\n* History of severe allergic or immunological reactions, such as difficult-to-control asthma\n* Pregnant or lactating women",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}